NSE/APOLLOHOSP

APOLLOHOSPApollo Hospitals Enterprise Ltd

Healthcare · NSE

₹7,699+1.93%

52-wk low52-WEEK RANGE52-wk high

₹6,722+14.5% from low ·-3.9% from high₹8,010

Price chart · 1M–10Y · daily-close

NSE bhavcopy + 10Y historical

APOLLOHOSP+12.66% · 1Y

Range high ₹8,099.5Range low ₹6,665Latest ₹7,699252 bars · daily-close · NSE bhavcopy + 10Y history

HealthcareMedical Care FacilitiesLargecapLow Risk

Stock scorecard

Auto-computed from latest ratios + sector context · not a buy/sell signal

Composite38/100

Performance

Medium

Middle-of-the-pack performance.

· 52w return +7.8%
· Just above 200-DMA (+2.6%)

Valuation

High

Looks expensive vs the sector.

· P/E 61.0 — 61% above sector median 37.8
· P/B 12.11 above sector median

Growth

Medium

Steady but not standout growth.

· Revenue YoY +17.2%
· Profit YoY +35.0% — strong earnings growth

Profitability

Medium

Average profitability vs peers.

· ROE 19.8%
· Net margin 6.6% — thin margins

DVM composite · Durability · Valuation · Momentum

Trendlyne-style 3-axis composite · all drivers shown below · not a buy/sell signal

CompositeC(57/100)

Durability

A+

85/100

Financially resilient — strong quality + solvency profile.

Show 4 drivers

Piotroski F-score8/9 (89pt)
Altman Z" score2.93 (100pt)
Debt/Equity0.84 (62pt)
ROE19.8% (79pt)

Valuation

19/100

Richly valued on most axes; limited margin of safety.

Show 4 drivers

P/E vs sector (61.0 / 37.8)161% (28pt)
P/B12.11 (18pt)
Dividend yield0.26% (7pt)
EV/EBITDA36.1 (8pt)

Momentum

67/100

Constructive setup — momentum building, not extended.

Show 5 drivers

52w change+7.8% (55pt)
DMA-trend alignmentup (75pt)
RSI (14)59.6 (95pt)
Price vs 200-DMA+3.3% (50pt)
MACD regimebullish (75pt)

Valuation positioning

Current ratio vs sector peer distribution

P/E (TTM)61.02

OVERVALUED

CheapestP/E 61.0 at 79th %ile — pricier than 79% of peers.Most expensive

P/B12.11

OVERVALUED

CheapestP/B 12.11 at 96th %ile of sector.Most expensive

EV/EBITDA36.10

OVERVALUED

Monthly seasonality

Avg monthly return over 11 years · historical — not a forecast

Best: Nov +5.53% · Worst: Mar -5.13%

Jan

+1.4%

55% win

Feb

+2.2%

58% win

Mar

-5.1%

33% win

Apr

+2.6%

67% win

May

-1.5%

36% win

Jun

+5.2%

Monthly return distribution

Distribution of 135 monthly returns

Mean

+1.75%

Median

+2.03%

Std dev

9.35%

Best

+33.5%

Worst

-34.4%

% positive

56%

SWOT analysis

Auto-derived from ratios + sector context + forensics · research only, not a recommendation

STRENGTHS · 3

Financial quality score 8/9
Piotroski ≥7 historically associated with outperformance
Bankruptcy risk low (Altman Z″ 2.93)
Z″ above 2.60 sits squarely in the 'safe' zone
Top quartile ROE in Healthcare
Rank 4 of 24 peers

WEAKNESSES · 1

Premium to sector on P/E (+61%)
P/E 61.0 vs Healthcare median 37.8

OPPORTUNITIES · 0

No strong near-term catalysts visible

THREATS · 1

Valuation compression risk
P/E 61.0 is 61% above sector — any growth miss gets punished

RETURNS · DAILY-CLOSE BASED

3Y+ shown as CAGR

+1.9%

+2.5%

+2.0%

+4.5%

+3.5%

+14.0%

+21.1%

+21.2%

10Y

+17.4%

Fundamentals

VALUATION

Market cap

₹1,10,096 Cr

P/E (TTM)

61.0

P/E (fwd)

46.0

next 12m

P/B

12.11

EV/EBITDA

36.1

Book value

₹632.45

per share

PROFITABILITY · QUALITY

ROE

19.8%

ROCE

—

Net margin

6.6%

Op margin

11.5%

Gross margin

34.3%

D/E

0.84

GROWTH · MARKET

Rev YoY

+17.2%

Profit YoY

+35.0%

Div yield

0.26%

Payout

15.2%

52w change

+7.8%

Beta

0.18

defensive

Pros and cons

Auto-derived from ratios · not a buy/sell recommendation

PROS · 2

+Forward P/E materially below trailing (46.0x vs 61.0x)Street expects earnings growth that compresses the multiple — positive surprise cushion
+Profit growing fast (+35.0% YoY)Operating leverage kicking in — bottom line out-growing top line

CONS · 2

−Trades at a premium to sector on P/EP/E 61.0 vs Healthcare median 37.8 — priced for more growth than peers
−Very high absolute P/E (61x)At this multiple the market prices in several years of strong growth upfront — risk of correction if growth disappoints

Sector-relative context

Healthcare · 24 peers

P/E (TTM)

This stock

61.02

Sector median

37.85

Rank 19/24 (25th %ile)

ROE

This stock

19.8%

Sector median

13.8%

Rank 21/24 (17th %ile)

P/B

This stock

12.11

Sector median

5.81

Rank 23/24 (8th %ile)

Quality score · Piotroski F-score

8 / 9

Strong quality — passes most F-score checks

✓Profitable (positive net income)· Most basic check — company makes money
✓Positive return on assets· Assets generate returns
✓Positive operating cash flow· Profits are backed by real cash, not accruals
✓Operating CF exceeds net profit· Healthy cash conversion — no aggressive revenue recognition
✓Long-term debt decreased YoY· Deleveraging — lower refinancing risk
✓ROA improved YoY· Getting more productive with the asset base
✓Operating margin expanded YoY· Pricing power or cost discipline
✗

Forensic score · Altman Z″ (emerging markets)

Bankruptcy-risk predictor · 1995 Altman emerging-market revision

SAFE2.93

Z″ = 2.93 — well inside the SAFE zone. Low bankruptcy risk signal across liquidity, profitability and solvency inputs.

Component	Ratio	Weight	Contribution
Working Capital / Total Assets (A)	0.237	×6.56	1.554
Retained Earnings / Total Assets (B)	0.126	×3.26	0.410
EBIT / Total Assets (C)	0.120	×6.72	0.804
Book Equity / Total Liabilities (D)	0.151	×1.05	0.159

Zones: Z″ ≥ 2.60 safe · 1.10–2.60 grey · < 1.10 distress. All four inputs derived from latest annual filing.

Analyst consensus

30 analysts · STRONG_BUY

Target mean

₹8750.23

Target high

₹9800.00

Target low

₹6230.00

Upside vs today

+14.3%

Street consensus target is +14.3% vs current price. Consensus is a lagging sentiment read, not a forecast.

Company + balance sheet snapshot

Industry

Medical Care Facilities

Employees

42,497

Shares out

14.4

Revenue (TTM)

₹24,215 Cr

EBITDA

₹3,213 Cr

Total debt

₹7,987 Cr

Cash

₹3,144 Cr

Net debt

₹4,843 Cr

Quarterly results

Last 5 quarters · ₹ Cr (Screener.in-grade depth)

Metric	2024-Q3	2024-Q4	2025-Q1	2025-Q2	2025-Q4
Revenue	5,589	5,527	5,376	5,842	6,477
Operating profit	631	577	570	637	746
OPM %	11.3%	10.4%	10.6%	10.9%	11.5%
Interest	118

Annual P&L

Last 4 years · ₹ Cr · all line items

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Revenue	14,536	16,445	18,862	21,577
Operating profit	1,588	1,449	1,707	2,276
OPM %	10.9%	8.8%	9.1%	10.6%
Interest	330	314	410	423

Peer	Last close	1Y change	Mcap ₹Cr	P/E	P/B	ROE	D/E	Rev YoY
APOLLOHOSPTHIS Apollo Hospitals Enterprise Limited	₹7,699	+7.8%	1,10,096	61.0	12.11	19.8%	0.84	+17.2%
DIVISLAB Divi's Laboratories Limited	₹6,229	+5.7%	1,66,714	67.2	10.81	16.1%	0.01	+12.3%
LUPIN Lupin Limited	₹2,326.1	+15.8%	1,06,756	23.0	5.43	—	0.32	+13.5%
DRREDDY Dr. Reddy's Laboratories Limited	₹1,235.7	+5.0%	1,02,626	18.2	2.76	16.1%	0.18	+4.4%
CIPLA Cipla Limited	₹1,240.8	-17.9%	99,317	21.9	3.02	13.8%	0.01	0.0%
MAXHEALTH Max Healthcare Institute Limited	₹1,007.65	-6.1%	98,448	69.7	9.85	—	0.33	+30.0%
MANKIND Mankind Pharma Limited	₹2,125	-17.9%	87,619	49.2	5.73	—	0.54	+18.1%
AUROPHARMA Aurobindo Pharma Limited	₹1,386	+15.4%	80,209	23.0	2.29	9.9%	0.22	+9.4%
ALKEM Alkem Laboratories Limited	₹5,582	+11.6%	67,578	28.5	5.06	17.8%	0.17	+2.3%

ASK AXEL

Dig deeper into APOLLOHOSP

Axel can fetch latest news, peer valuation, consensus estimates, insider activity, and concall commentary for APOLLOHOSP — all in one sourced reply.

Ask free in chat

Run these tools on APOLLOHOSP

Historical return →

"If I had bought APOLLOHOSP in year X"

Rolling returns →

Worst/best 1/3/5/7/10-yr windows

Buy-the-dip backtester →

Dip-buying vs SIP on APOLLOHOSP

Brokerage + charges →

All-in cost for trading APOLLOHOSP

Research tool · not investment advice.

Axel Markets is an information + analytics product. We are not a SEBI-registered Research Analyst (RA) or Investment Adviser (IA). Nothing on this page is a buy, sell, or hold recommendation. Past performance is not indicative of future returns. Verify all data against the authoritative source (NSE, BSE, AMFI, SEBI, company RHP / factsheet) before acting. Daily OHLCV sourced primarily from our NSE bhavcopy ingest (public sec_bhavdata_full CSV), with Stooq as a fallback for historical gaps. Split + bonus adjusted. Excludes dividends. Not a recommendation. Past performance does not predict future returns. For authoritative live quotes see NSE / BSE directly.

Quarter	EPS estimate	EPS actual	Surprise %
-1q	33.38	35.95	+7.7%
-2q	34.19	33.19	-2.9%
-3q	26.19	30.10	+14.9%
-4q	27.22	27.10	-0.4%

Date	Amount
2026-02-16	₹10.00
2025-08-19	₹10.00
2025-02-14	₹9.00
2024-08-16	₹10.00
2024-02-20	₹6.00
2023-08-18	₹9.00
2023-02-24	₹6.00
2022-08-18	₹11.75
2021-08-18	₹3.00
2020-09-17	₹2.75
2020-02-25	₹3.25
2019-09-12	₹6.00
2018-09-12	₹5.00
2017-09-07	₹6.00

Metric	2022-FY	2023-FY	2024-FY	2025-FY
Equity capital	72	72	72	72
Reserves	1,670	2,059	2,773	3,941
Borrowings	4,068	4,332	5,333	5,419
Other liabilities	19	20	18	17
Total liabilities	13,269	14,428	16,753	20,657
Fixed assets	7,348	8,117	9,461	10,739
CWIP	103	685	921	923
Investments	154	253	144	879
Other assets	7	6	3	3
Total assets	13,269	14,428	16,753	20,657

Metric	2022-FY	2023-FY	2024-FY	2025-FY
CF Operating	1,696	1,377	1,920	2,136
CF Investing	-847	-871	-1,537	-3,381
CF Financing	-792	-633	-311	1,317
Net cash flow	158	-113	72	73
Free cash flow	1,039	248	783	424

Metric	2025-FY	2024-FY	2023-FY	2022-FY
OPM %	10.6%	9.1%	8.8%	10.9%
Net margin %	6.7%	4.8%	5.0%	7.3%
ROE %	42.2%	36.1%	42.3%	60.6%
ROCE %	28.0%	24.5%	23.7%	32.8%
Debt / Equity	1.35	1.87	2.03	2.34
Dividend payout %	19%	24%	31%	4%
Interest coverage	5.8×	4.4×	4.6×	5.8×
Revenue growth YoY	+14.4%	+14.7%	+13.1%	—
Profit growth YoY	+60.9%	+9.7%	-22.4%	—

APOLLOHOSPApollo Hospitals Enterprise Ltd

Price chart · 1M–10Y · daily-close

Stock scorecard

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

SWOT analysis

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Peer comparison · Healthcare

Ask Axel about APOLLOHOSP

Recent news

Dig deeper into APOLLOHOSP

Run these tools on APOLLOHOSP

Technical snapshot

Earnings history + surprises

Dividends + splits history

Recent news

Stock scorecard

SWOT analysis

DVM composite · Durability · Valuation · Momentum

Valuation positioning

Monthly seasonality

Monthly return distribution

Fundamentals

Pros and cons

Sector-relative context

Quality score · Piotroski F-score

Forensic score · Altman Z″ (emerging markets)

Analyst consensus

Company + balance sheet snapshot

Quarterly results

Annual P&L

Balance sheet

Cash flow statement

Ratios

Peer comparison · Healthcare